AZ expands phase 3 trials of COVID-19 vaccine frontrunner into US
pharmaphorum
SEPTEMBER 1, 2020
AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.
Let's personalize your content